BridgeMD
New treatment option for Parkinsons Disease (PD)
Official title Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
ClinicalTrials.gov ID: NCT07064005
What this study is testing
What is Gamma- glutamylcysteine?
Gamma- glutamylcysteine is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for parkinsons disease (pd).
Also referred to as GGC.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 80
You may be able to join if
- Confirmed Parkinson's Disease diagnosis.
- Montreal Cognitive Assessment (MoCA) greater than or equal to 26.
- Age (50 to 80 years of age).
- Ability to read and write in English.
You likely can't join if
- Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.
- people with claustrophobia.
- Patients with a clinical diagnosis of Parkinson's disease dementia or dementia with Lewy bodies.
- people with a history of cancer.
- people with active psychosis or delirium.
- people with chronic kidney (creatinine \> 1.5mg/dL) or liver disease (AST ≥ 1.5 ULN; ALT ≥ 1.5 ULN) within 30 days prior to enrolment.
See the full eligibility criteria
- Confirmed Parkinson's Disease diagnosis.
- Montreal Cognitive Assessment (MoCA) greater than or equal to 26.
- Age (50 to 80 years of age).
- Ability to read and write in English.
- Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.
- people with claustrophobia.
- Patients with a clinical diagnosis of Parkinson's disease dementia or dementia with Lewy bodies.
- people with a history of cancer.
- people with active psychosis or delirium.
- people with chronic kidney (creatinine \> 1.5mg/dL) or liver disease (AST ≥ 1.5 ULN; ALT ≥ 1.5 ULN) within 30 days prior to enrolment.
- people on antioxidant therapy (ashwagandha, gingko biloba or N-acetylcysteine) or illicit drug abuse/dependence (cocaine, heroin, marijuana, or fentanyl).
- people with previous traumatic head injury.
The study team makes the final eligibility decision.
Where it's taking place
- Pittsburgh, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Pittsburgh, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.